- The approval means that medical professionals in Australia can now use the company’s COVID-19 blood test, AtomoRapid
- The product will now added to Atomo’s Australian Register of Therapeutic Goods (ARTG) listing, with the HIV Self-Test
- AtomoRapid jointly manufactured by Atomo and a French company, NG Biotech
- NG manufactures the test strip, while Atomo manufactures the device
- Atomo co-founder and Managing Director, John Kelly, pleased with the approval
- Atomo is up 8.82 per cent on the market this morning and is trading for 37 cents per share